Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Archives
Print | Email | Share | Comments (2)

Novo Nordisk Files for FDA Approval of New Insulin


Oct 15, 2011

Novo Nordisk's insulin degludec is injected once daily.

A brand new insulin will soon be on pharmacy shelves in the United States if Danish pharmaceutical company Novo Nordisk has its way. The company has filed for approval from the Food and Drug Administration to sell insulin degludec, an original formulation that lasts an extra-long time.

Insulin degludec is injected only once a day. Once under the skin, the dose of insulin is absorbed slowly and consistently, allowing for better nighttime control, according to Novo. Most importantly, test subjects had a low rate of hypoglycemia on the drug.

"We are very excited about being able to file for the approval of insulin degludec and insulin degludec/insulin aspart now also in the US," said Novo Executive Vice President and Chief Science Officer Mads Krogsgaard Thomsen. "This is another significant milestone for Novo Nordisk and for the millions of people with diabetes who require insulin."

As Thomsen mentioned, the company is also applying for approval of a dual formulation of insulin degludec and insulin aspart. In this combination, the long-lasting degludec is accompanied by the short-term aspart. An injection would therefore offer both 24-hour control and a needed bolus after a meal.

Extensive clinical trials have been undertaken to test the safety and efficacy of insulin degludec. The BEGIN and BOOST studies, which wrapped up last year, included nearly 10,000 people with type 1 or type 2 diabetes. Results from the studies showed that the insulin was indeed effective as a 24-hour treatment.

Novo Nordisk, which has a global reach, has spent nearly 90 years in the diabetes care field. Some of its best-known products include Levemir and NovoLog. Novo has also branched into hemophilia care, hormone replacement therapy, and growth hormone therapy.


Source:
http://press.novonordisk-us.com/index.php?s=43&item=304


Categories: BEGIN Study, BOOST Study, Diabetes, Diabetes, Food, Hypoglycemia, Injection, Insulin, Insulin Aspart, Insulin Degludec, Novo Nordisk, Type 2 Issues



You May Also Be Interested In...


Comments

Posted by Anonymous on 17 October 2011

I'm not sure I understand why you would combine the long/short insulins unless you are trying to avoid one shot at mealtime if timed with the long acting analog. I would go off the insulin pump and back on shots if this can prove effective. I have been a pump user for 14 years and its no picnic and my sites are becoming very damaged...

Posted by Anonymous on 18 October 2011

Levemir was supposed to be a 24 hour drug too, but it only lasts 20 hours... sometimes only lasting for 12 hours in some diabetics. Their competition Lantus is also supposed to be a 24 hour drug, but lasts for up to 22 hours. I hope this new drug works, but will be doing much research on it before it gets into my bloodstream for the first time. I would prefer them find a better bolus insulin versus re-hashing their basal insulins.


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.